Generic Name: pegloticase
Dosage Form: injection, solution
WARNING: ANAPHYLAXIS AND INFUSION REACTIONS
Anaphylaxis and infusion reactions have been reported to occur during and after administration of Krystexxa. [see Warnings and Precautions (5.1, 5.2)]
Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported.
Krystexxa should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions.
Patients should be premedicated with antihistamines and corticosteroids.
Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of Krystexxa.
Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.
Indications and Usage for Krystexxa
Krystexxa® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.
Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Important Limitations of Use:
Krystexxa is not recommended for the treatment of asymptomatic hyperuricemia.
Krystexxa Dosage and Administration
Dosage
The recommended dose and regimen of Krystexxa for adult patients is 8 mg (uricase protein) given as an intravenous infusion every two weeks.
The optimal treatment duration with Krystexxa has not been established.
Preparation
Visually inspect Krystexxa for particulate matter and discoloration before administration, whenever solution and container permit. Do not use vials if either is present. [see Dosage Forms and Strengths (3)]
Use appropriate aseptic technique. Withdraw 1 mL of Krystexxa from the vial into a sterile syringe. Discard any unused portion of product remaining in the 2 mL vial. Inject into a single 250 mL bag of 0.9% Sodium Chloride Injection, USP or 0.45% Sodium Chloride Injection, USP for intravenous infusion. Do not mix or dilute with other drugs.
Slideshow: Psoriasis: Treatment Options to Manage Your Symptoms
Invert the infusion bag containing the dilute Krystexxa solution a number of times to ensure thorough mixing. Do not shake.
Krystexxa diluted in infusion bags is stable for 4 hours at 2° to 8°C (36° to 46°F) and at room temperature (20° to 25°C, 68° to 77°F). However it is recommended that diluted solutions be stored under refrigeration, not frozen, protected from light, and used within 4 hours of dilution. [see How Supplied/Storage and Handling (16)]
Before administration, allow the diluted solution of Krystexxa to reach room temperature. Krystexxa in a vial or in an intravenous infusion fluid should never be subjected to artificial heating (e.g., hot water, microwave).
Administration
Do not administer as an intravenous push or bolus.
It is recommended that before starting Krystexxa patients discontinue oral urate-lowering medications and not institute therapy with oral urate-lowering agents while patients are on Krystexxa therapy.
|
